Learn about the role type 2 inflammation plays in the burden and pathophysiology of severe asthma in pediatric patients.
This interactive tool allows you to explore the global burden of AD in pediatric patients <12 years from the PEDISTAD Study.
Learn about the multifaceted burden of uncontrolled pediatric asthma on patients and their caregivers.
Join Dr. Leonard Bacharier as he discusses the definition of clinical remission in pediatric asthma and how it can represent a potential target in pediatric asthma management.
Join experts Drs. Amy Paller and Peter Lio at an educational symposium as they investigate atopic dermatitis as a risk factor for the development of food allergies. The speakers will also discuss the benefits of early intervention in pediatric atopic dermatitis and the potential for disease modification.
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Thomas Bieber discusses how early dupilumab intervention in pediatric atopic dermatitis may alter the atopic march, reducing the risk of developing atopic comorbidities as well as nonatopic comorbidities such as infections and psychosomatic issues.
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares discusses evidence demonstrating that dupilumab reduces both total and allergen-specific IgE in pediatric patients with atopic dermatitis and comorbid allergic diseases, underscoring the role of IL-4/IL-13 blockade in modulating B-cell activity.
An interactive tool used to explore the global burden of atopic dermatitis in children and adolescents.
Inflammatory processes drive AD both within and beyond the skin, leading to significant, cumulative life impacts. Early intervention has the potential to mitigate these impacts by altering the disease course.
Join pediatric respirologist Dr. Sharon Dell and adult respirologist Dr. Simon Couillard as they discuss the prognostic and diagnostic power of asthma biomarkers and their impact on optimizing patient management across all ages.
Watch highlights from the AAAAI 2023 Conference in San Antonio, TX, USA.
Dr. Paller presents the Pediatric Eczema Elective Registry (PEER) findings, which suggest early-onset of AD is associated with higher risk of persistence of disease.